Whalesbook
Toh bhaiyo, Cellogen Therapeutics ne ₹20 crore ka fund raise kar liya hai, aur is deal ko Kotak Alternate Asset Managers ne lead kiya hai. Ye paisa aane se unka focus CAR-T aur gene therapy programs par aur strong hoga, special karke unke unique bispecific CAR-T candidate par. Company ka target hai ki cancer patients ke liye CAR-T therapy ko $60,000 se $70,000 tak laaye, jo globally abhi $500,000 se $700,000 tak hai. Matlab, life-saving treatments ko India mein accessible banane ka bada plan hai.
Ye jo Kotak Life Sciences Fund I ke through investment hui hai, ye India ke booming biotech sector mein ek important sign hai. India mein already 11,000 se zyada startups hain aur government bhi 'Biopharma SHAKTI' jaise schemes se support kar rahi hai. Plus, apna drug regulator bhi advanced therapies ke liye ready ho raha hai. Yahan tak ki, India ne apna pehla homegrown CAR-T therapy, ImmunoACT ka NexCAR19, approve kiya hai, jo global prices se kaafi cheaper hai. Yeh sab dekh ke lagta hai ki Cellogen jaise companies ke liye ek clear path ban raha hai.
Aur haan, ye pehli baar nahi hai jab Cellogen ko achha fund mila hai. Pehle Natco Pharma ne bhi around ₹15 crore invest kiye the unki 5.38% stake ke liye, jo dikhata hai ki investors ka bharosa bana hua hai.
Lekin bhai, sab kuch itna bhi aasan nahi hai. Cellogen ka target price, yaani $60,000-$70,000, woh ImmunoACT ke NexCAR19 se abhi bhi zyada hai, jo $20,000 se $50,000 mein aata hai. Toh Indian market mein competition tough hoga. Bispecific CAR-T develop karna bhi manufacturing aur regulatory ke hisab se complicated hai. Production ko affordable banana ek bada challenge hai. Aur unka Phase I trials ke liye Christian Medical College Vellore par depend karna bhi ek factor hai.
Abhi Cellogen apni bispecific CAR-T technology ko prove karne ke liye ye naya funding use karegi. Unka Phase I trials complete karna aur manufacturing ko scale up karna next crucial steps honge. Indian regulations aur biotech industry ki growth unke liye achha environment de rahi hai. Unko sirf therapy ke clinical benefits nahi, balki ek sustainable aur competitive cost structure bhi dikhana hoga taaki patients tak easily pahunch sakein.